Peroxisome Proliferator-Activated Receptor Gamma Agonists in Kidney Disease - Future Promise, Present Fears

被引：20
作者：
Mao, Zhiguo [1 ,2 ,3 ]
Ong, Albert C. M. [1 ,2 ]
机构：
[1] Univ Sheffield, Sch Med, Henry Wellcome Labs Med Res, Kidney Genet Grp,Acad Unit Nephrol, Sheffield S10 2RX, S Yorkshire, England
[2] Sheffield Teaching Hosp Fdn Trust, No Gen Hosp, Sheffield Kidney Inst, Sheffield, S Yorkshire, England
[3] Second Mil Med Univ, Changzheng Hosp, Div Nephrol, Shanghai, Peoples R China
来源：
NEPHRON CLINICAL PRACTICE | 2009年 / 112卷 / 04期
关键词：
PPAR-gamma agonists; Thiazolidinediones; Kidney disease; Diabetes mellitus; TYPE-2; DIABETES-MELLITUS; ISCHEMIA-REPERFUSION INJURY; URINARY ALBUMIN EXCRETION; CONGESTIVE-HEART-FAILURE; PPAR-GAMMA; ROSIGLITAZONE TREATMENT; RENAL-DISEASE; NONALCOHOLIC STEATOHEPATITIS; MYOCARDIAL-INFARCTION; CARDIOVASCULAR DEATH;
D O I：
10.1159/000224789
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The peroxisome proliferator-activated receptor superfamily (PPARs) comprises a class of nuclear receptors with significant effects in regulating multiple cellular pathways. Much research and clinical interest has surrounded the PPAR-gamma isoform because of its key role in the transcriptional regulation of metabolic pathways and the efficacy of thiazolidinediones, the most clinically used PPAR-gamma agonist, in the management of type 2 diabetes mellitus. In this review, we discuss the pathogenic role of PPAR-gamma in experimental models of kidney disease, clinical trials of thiazolidinediones in diabetic and non-diabetic kidney disease, recent safety concerns surrounding PPAR-gamma agonists and reflect on their potential use in 'orphan' kidney diseases. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码：C230 / C240
页数：11
相关论文
共 87 条
[1]   Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy [J].
Agarwal, R .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2006, 290 (03) :F600-F605
[2]   Insulin and angiotensin II are additive in stimulating TGF-beta 1 and matrix mRNAs in mesangial cells [J].
Anderson, PW ;
Zhang, XY ;
Tian, J ;
Correale, JD ;
Xi, PX ;
Yang, D ;
Graf, K ;
Law, RE ;
Hsueh, WA .
KIDNEY INTERNATIONAL, 1996, 50 (03) :745-753
[3]  
Arima S, 2002, J AM SOC NEPHROL, V13, P342, DOI 10.1681/ASN.V132342
[4]   Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent [J].
Artis, Dean R. ;
Lin, Jack J. ;
Zhang, Chao ;
Wang, Weiru ;
Mehra, Upasana ;
Perreault, Mylene ;
Erbe, David ;
Krupka, Heike I. ;
England, Bruce P. ;
Arnold, James ;
Plotnikov, Alexander N. ;
Marimuthu, Adhirai ;
Nguyen, Hoa ;
Will, Sarah ;
Signaevsky, Maxime ;
Kral, John ;
Cantwell, John ;
Settachatgull, Calvin ;
Yan, Douglas S. ;
Fong, Daniel ;
Oh, Angela ;
Shi, Shenghua ;
Womack, Patrick ;
Powell, Benjamin ;
Habets, Gaston ;
West, Brian L. ;
Zhang, Kam Y. J. ;
Milburn, Michael V. ;
Vlasuk, George P. ;
Hirth, K. Peter ;
Nolop, Keith ;
Bollag, Gideon ;
Ibrahim, Prabha N. ;
Tobin, James F. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (01) :262-267
[5]   Rosiglitazone reduces urinary albumin excretion in type II diabetes [J].
Bakris, G ;
Viberti, G ;
Weston, WM ;
Heise, M ;
Porter, LE ;
Freed, MI .
JOURNAL OF HUMAN HYPERTENSION, 2003, 17 (01) :7-12
[6]   Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria [J].
Bakris, George L. ;
Ruilope, Luis M. ;
McMorn, Stephen O. ;
Weston, Wayde M. ;
Heise, Mark A. ;
Freed, Martin I. ;
Porter, Lisa E. .
JOURNAL OF HYPERTENSION, 2006, 24 (10) :2047-2055
[7]   Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes [J].
Basu, A ;
Jensen, MD ;
McCann, F ;
Mukhopadhyay, D ;
Joyner, MJ ;
Rizza, RA .
DIABETES CARE, 2006, 29 (03) :510-514
[8]   Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-γ agonist:: Molecular mechanism of the antiproteinuric effect of pioglitazone [J].
Benigni, Ariela ;
Zoja, Carla ;
Tomasoni, Susanna ;
Campana, Marco ;
Corna, Daniela ;
Zanchi, Cristina ;
Gagliardini, Elena ;
Garofano, Elvira ;
Rottoli, Daniela ;
Ito, Takahito ;
Remuzzi, Giuseppe .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (06) :1624-1632
[9]   Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets [J].
Brown, Jonathan D. ;
Plutzky, Jorge .
CIRCULATION, 2007, 115 (04) :518-533
[10]   The pharmacokinetics of pioglitazone in patients with impaired renal function [J].
Budde, K ;
Neumayer, HH ;
Fritsche, L ;
Sulowicz, W ;
Stompôr, T ;
Eckland, D .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (04) :368-374
123456789